Company: LGN
Filing Date: 2025-07-15
Form Type: DRS/A
Source: 0000950123-25-006399
Chunk: 101

Company: Legence Corp.
Filing Date: 2025-07-15
Form: DRS/A
Chunk 101
---
. SOFR loans bear interest at a rate equal to SOFR plus a margin of either 2.75%, 3.00% or 3.25%, which margin is determined based on the Company’s most recently reported
Consolidated First Lien Net Leverage Ratio (the “First Lien Net Leverage Ratio”), generally defined as the ratio of first lien secured indebtedness (net of cash) to consolidated pro forma adjusted EBITDA for the preceding four fiscal
quarters. SOFR loans are subject to a floor of 0.75%. Interest on SOFR loans is payable (a) based on the selected interest period if such interest period is less than three months or (b) quarterly if the selected interest period is three
months or longer. Base rate loans bear interest at a rate equal to either 1.75%, 2.00% or 2.25%, which margin is determined based on the Company’s most recently reported First Lien Net Leverage Ratio, plus the base rate, which is equal to the
greater of (a) the federal funds rate plus 0.50%, (b) the prime rate and (c) one-month SOFR plus 1.00%. Interest on base rate loans is payable quarterly. The interest rate applicable to the term
loans was 7.57%, 7.96%, 8.96%, and 8.13% as of March 31, 2025, December 31, 2024, December 31, 2023 and December 31, 2022, respectively.

See the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and
Capital Resources—Debt.”

Assuming no exercise of the underwriters’ option to purchase additional shares, a $1.00 change in
the

assumed initial public offering price of $ per share (the midpoint of the price range set forth on the cover of this
prospectus) would cause the net proceeds from this offering, after deducting the underwriting discounts and commissions and estimated offering expenses, received by us to change by $ million, assuming no change to the
number of shares offered by us, as set forth on the cover page of this prospectus. Similarly, a one million change in the number of shares sold in this offering by us would cause the net proceeds

62

Confidential Treatment Requested by Legence Corp.

Pursuant to 17 C.F.R. Section